Literature DB >> 16188579

Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.

Chin-Hsiao Tseng1, Tien-Shang Huang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16188579     DOI: 10.1016/j.diabres.2004.11.003

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


× No keyword cloud information.
  4 in total

1.  Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.

Authors:  Chin-Hsiao Tseng
Journal:  BMC Cancer       Date:  2022-05-18       Impact factor: 4.638

Review 2.  Pioglitazone for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C Clar; S H Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

3.  Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients.

Authors:  Chin-Hsiao Tseng
Journal:  Aging (Albany NY)       Date:  2019-05-14       Impact factor: 5.682

4.  Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.

Authors:  Chin-Hsiao Tseng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.